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Background: Data from the Czech national registry were analysed retrospectively to describe treatment outcomes
for capecitabine and oxaliplatin (XELOX) regimen with bevacizumab versus 5-fluorouracil, leucovorin, and oxaliplatin
(FOLFOX) regimen with bevacizumab in the first-line therapy for metastatic colorectal cancer (mCRC).
Methods: A national registry containing anonymised individual data on patients treated with targeted therapies
was used as a data source. In total, 2,191 mCRC patients who received a first-line therapy with bevacizumab
combined with either FOLFOX regimen (n = 1,218, 55.6%) or XELOX regimen (n = 973, 44.4%) were included in the
present analysis.
Results: No statistically significant difference in survival was observed between the two groups, with median overall
survival (OS) of 27.0 months (95% confidence interval [CI] 24.6-29.5 months) and 30.6 months (95% CI 27.8-33.4 months)
for FOLFOX/bevacizumab and XELOX/bevacizumab, respectively (p = 0.281). Median progression-free survival (PFS) was
11.4 months (95% CI 10.7-12.1 months) for FOLFOX/bevacizumab and 11.5 months (95% CI 10.8-12.3 months) for
XELOX/bevacizumab (p = 0.337). The number of metastatic sites was identified as the most significant predictor of PFS
and, together with the presence/absence of metastatic disease at diagnosis, also for OS.
Conclusions: According to this large registry-based analysis, XELOX and FOLFOX regimens have similar effectiveness
for use in combination with bevacizumab in the first-line treatment of mCRC. Multiple metastatic sites and the
presence of metastatic disease at diagnosis were the strongest negative predictors of OS regardless of backbone
chemotherapy regimen.
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Bevacizumab, a monoclonal antibody against vascular
endothelial growth factor (VEGF), is currently an im-
portant component of standard therapeutic regimens for
metastatic colorectal cancer (mCRC). A randomised trial
has demonstrated the efficacy of bevacizumab in com-
bination with irinotecan, bolus 5-fluorouracil (5FU), and
leucovorin (IFL) [1]. The combinations of capecitabine
and oxaliplatin (XELOX) and infusional 5FU, leucovorin,
and oxaliplatin (FOLFOX) with bevacizumab are widely
used in clinical practice as the first line treatment for
mCRC, although the benefit of adding bevacizumab to
FOLFOX or XELOX was smaller in the NO16966 ran-
domised trial than that reported for the IFL regimen [2].
In addition, no differences in progression-free survival
(PFS) or overall survival (OS) were observed in a phase
III study of patients treated with the 5FU, leucovorin,
and irinotecan with or without bevacizumab in the first
line [3]. Nevertheless, bevacizumab significantly pro-
longed both OS and PFS when added to FOLFOX in the
E3200 randomised trial enrolling patients pretreated
with a fluoropyrimidine and irinotecan [4]. Adding more
uncertainty about the role of bevacizumab combined
with fluoropyrimidine/oxaliplatin chemotherapy, an un-
planned analysis of the NO16966 study has suggested
that FOLFOX/bevacizumab is not superior to FOLFOX
alone although XELOX/bevacizumab was superior to
XELOX alone [5].
The aim of the present registry-based study was to ex-
plore possible differences in outcomes of patients treated
with bevacizumab and either XELOX or FOLFOX using
data from the Czech national registry of mCRC patients
containing 2,191 individual entries of patients treated with
XELOX/bevacizumab or FOLFOX/bevacizumab combi-
nation for mCRC in the first line.
Methods
Patient database
The clinical registry CORECT (http://corect.registry.cz/)
is a non-interventional post-registration database of epi-
demiological and clinical data of patients with mCRC
treated with targeted therapies including bevacizumab,
cetuximab, and panitumumab in the Czech Republic. In
the Czech Republic the administration of targeted therapy
outside of clinical trials is limited to comprehensive cancer
centres and these drugs are reimbursed only when admi-
nistered in one of these centres. The CORECT registry
was created in 2011 by merging individual registries for
targeted agents used in mCRC, including bevacizumab,
cetuximab, and panitumumab. The registry contains ano-
nymised individual patient data including demographic
parameters, initial staging and disease characteristics,
baseline patient information at the start of targeted the-
rapy, and data on survival and adverse events. Data areentered into the database by all Czech comprehensive
cancer centres administering targeted therapy and up-
dated at least twice yearly for patients who continue treat-
ment with targeted agents.
The study has been carried out in compliance with the
Helsinki declaration and the registry has been approved
by institutional ethical committees of the participating
comprehensive cancer centres (the list of the centres
can be found at http://corect.registry.cz/index-en.php?
pg=participating-centres).Patients and treatment
Patients who received first-line therapy for mCRC with
bevacizumab and either FOLFOX or XELOX were in-
cluded in the present analysis. FOLFOX4 regimen is the
predominant schedule used in most Czech centres (oxali-
platin 85 mg/m2 intravenously [i.v.] on day 1, leucovorin
200 mg/m2 i.v. on days 1 and 2, 5FU 400 mg/m2 i.v. bolus
od days 1 and 2, and 5FU 600 mg/m2 22-hour i.v. infusion
on day 1, 14-day cycle) and was administered with beva-
cizumab 5 mg/kg i.v. on day 1 or 3 of each cycle (Saltz
et al. [2]). However, FOLFOX6 and FOLFOX7 regimens
have been used in some centres. XELOX (capecitabine
1000 mg/m2 twice daily orally on days 1–14, oxaliplatin
130 mg/m2 i.v. on day 1, 21-day cycle) was administered
with bevacizumab 7.5 mg/kg on day 1 of each cycle [2].
Disease responses were assessed using the RECIST 1.1
criteria. Dose modifications were at the discretion of
attending oncologist. To ensure adequate follow-up, only
patients who started bevacizumab and chemotherapy at
least six months prior to the data cut-off (regardless of the
number of received treatment cycles) were included in the
present analysis Query systems were in place for reported
clinically significant toxicities.Statistical analysis
Standard descriptive statistics were used to describe the
data. Differences in initial categorical parameters were
assessed using the Fisher exact test; the Pearson chi-
square test was applied when there were more than two
categories. Comparisons of the treatment groups for con-
tinuous variables were based on the Mann–Whitney test.
Both overall survival (OS) and progression-free survival
(PFS) were calculated since the start of the bevacizumab-
containing regimen. The survival was estimated using the
Kaplan–Meier method. Log-rank test was used to com-
pare OS and PFS. Multivariable Cox proportional hazards
model was used to quantify the influence of the consi-
dered treatment modalities on survival in the presence of
other potential predictive and prognostic factors. Model
optimisation was performed via analysis of deviance and
model residuals. The standard level of statistical signifi-
cance at α = 0.05 was used. Differences in the occurrence
Table 1 Baseline characteristics of patients




Males, n (%) 755 (62.0) 641 (65.9) 0.060
Age at treatment initiation 0.859
Median, (5%-95%) 61 (43–73) 62 (43–73)
Localization, n (%) 0.235
Colon 717 (58.9) 596 (61.3)
Rectum 500 (41.1) 377 (38.7)
Not available 1 (0.1) 0 (0.0)
Thromboembolism, n (%) 44 (3.6) 36 (3.7) 0.923
Hypertension, n (%) 473 (40.4) 357 (39.0) 0.511
Primarily metastatic, n (%) 0.021*
M0 399 (32.8) 365 (37.5)
M1 819 (67.2) 608 (62.5)
Histological type, n (%) 0.123
Adenocarcinoma 1177 (96.6) 927 (95.3)
Other 22 (1.8) 18 (1.8)
Not available 19 (1.6) 28 (2.9)
PS, n (%) <0.001*
0 293 (24.1) 255 (26.2)
1 303 (24.9) 130 (13.4)
2 46 (3.8) 14 (1.4)
3 2 (0.1) 0 (0.0)
4 1 (0.1) 0 (0.0)
Not available 573 (47.0) 574 (59.0)
Radiotherapy, n (%) 0.235
Adjuvant 84 (6.9) 84 (8.6)
Neo-adjuvant 112 (9.2) 112 (11.5)
Other 18 (1.5) 14 (1.4)
No radiotherapy 998 (81.9) 758 (77.9)
Not available 5 (0.4) 5 (0.5)
Neo-adjuvant therapy, n (%) 99 (8.2) 89 (9.2) 0.396
Adjuvant therapy, n (%) 288 (23.7) 262 (27.1) 0.068
*Statistically significant difference.
Buchler et al. BMC Cancer 2014, 14:323 Page 3 of 7
http://www.biomedcentral.com/1471-2407/14/323of adverse effects between the two chemotherapy regi-
mens were analysed using the Fisher exact test.
Results
Patient cohort
The CORECT registry included data of 4,024 mCRC pa-
tients from Czech comprehensive cancer centres who
started treatment with bevacizumab between December
2005 and March 2012. Most patients (n = 3,964, 98.5%)
initially received bevacizumab in combination with che-
motherapy. In total, 2,191 mCRC patients (54.4% of all
patients treated with bevacizumab during that period)
who received a first-line therapy with bevacizumab com-
bined with either FOLFOX regimen (n = 1,218, 55.6%) or
XELOX regimen (n = 973, 44.4%) and had evaluable data
as defined above were included in the present analysis.
Baseline patient characteristics are shown in Table 1. As
of 31 March 2012, the median follow-up was 15.9 months
(range 0.1-74.0 months), with 167 (13.7%) and 133 (14.2%)
patients remaining on FOLFOX/bevacizumab or XELOX/
bevacizumab, respectively.
The best treatment responses during the first-line
therapy with FOLFOX/bevacizumab or XELOX/bevacizu-
mab, respectively, were as follows: complete response 176
(14.4%) versus 129 (13.3%); partial response 397 (32.6%)
versus 303 (31.1%); stable disease 383 (31.4%) versus 394
(40.5%); progressive disease 183 (15.0%) versus 63 (6.5%)
(p < 0.001). Best response was not evaluable for 79 (6.5%)
and 84 (8.7%) patients, respectively.
Median PFS was 11.4 months (95% confidence interval
[CI] 10.7-12.1 months) for patients receiving bevacizumab
and FOLFOX and 11.5 months (95% CI 10.8-12.3 months)
for patients treated with bevacizumab and XELOX
(Figure 1). This difference was not statistically significant
(p = 0.337). Median OS was 27.0 months (95% CI 24.6-
29.5 months) for patients receiving bevacizumab and
FOLFOX and 30.6 months (95% CI 27.8-33.4 months) for
patients treated with bevacizumab and XELOX (Figure 2).
No statistically significant difference in OS was observed
between the two treatment groups (p = 0.281).
To adjust for the influence of other potential predictive
and prognostic factors, multivariable Cox model for both
PFS (Table 2) and OS (Table 3) was performed. The
chemotherapy regimen was not significantly associated
with PFS (HR = 0.95, p = 0.400). Although sex, age, and
site of primary tumour were not found to be associated
with PFS, they were left in the final multivariable model as
adjusting variables. The number of metastatic sites was
identified as the most significant predictor of PFS (two
metastatic sites: HR = 1.39, p < 0.001; three and more
metastatic sites: HR = 1.66, p < 0.001).
Moreover, the multivariable Cox model for PFS was
also applied on the subset of patients with available in-
formation on the performance status (n = 1,044). As inthe whole dataset, the chemotherapy regimen was not
found to have significant effect on PFS (HR = 1.03,
p = 0.730), whereas the number of metastatic sites was
confirmed as the strongest prognostic factor with re-
spect to PFS. The performance status at the onset of
targeted therapy was not found to be significantly asso-
ciated with PFS. However, almost all (94.0%) patients
with available performance status information in our co-
hort had a performance status of 0 or 1.
The results of the multivariable Cox model for OS are
shown in Table 3. As for PFS, the chemotherapy regimen
was not associated with OS (HR = 0.91, p = 0.290). Meta-
static disease at presentation (synchronous metastases)
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Figure 1 Progression-free survival of mCRC patients treated
with bevacizumab in combination with FOLFOX or XELOX.
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dictors of OS.
A univariate analysis has been carried out for different
subgroups of patients. No particular group of patients
could be identified that would profit more from FOLFOX
versus XELOX backbone chemotherapy or vice versa
(Table 4). Of note, wild-type KRAS oncogene status was
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Figure 2 Overall survival of mCRC patients treated with
bevacizumab in combination with FOLFOX or XELOX.bevacizumab cohort (38.8 months versus 28.4 for KRAS
wild-type versus mutated, respectively; p = 0.056) but was
not prognostic in the FOLFOX/bevacizumab cohort
(31.3 months versus 31.5 months, respectively; p = 0.53).
Treatment toxicity
Only toxicities considered to be related to bevacizumab
were reported to the database. Safety data are sum-
marised in Table 5. Significant (i.e. grade 3–5) adverse
events were rarely reported. As expected, the most com-
mon significant adverse event irrespective of the chemo-
therapy regimen was hypertension. Bleeding occurred
more frequently in the FOLFOX/bevacizumab cohort
while diarrhoea was reported more frequently during
XELOX/bevacizumab treatment. Three cases of gastro-
intestinal perforation were reported, all occurring in the
FOLFOX/bevacizumab cohort.
Discussion
The present registry-based retrospective analysis suggests
that the combination of bevacizumab with XELOX had
similar efficacy as an infusional regimen combining beva-
cizumab with FOLFOX. This result is in agreement with
published results of randomised clinical trials that demon-
strated comparable efficacies of XELOX and FOLFOX)
alone or in combination with bevacizumab [2,6,7]. In
addition, three registry-based studies examining bevacizu-
mab efficacy in mCRC have been published, including the
prospective Bevacizumab Expanded Access Trial (BEAT)
study, the prospective Bevacizumab Regimens’ Investi-
gation of Treatment Effects (BRiTE) observational study,
and the retrospective Medicare-based analysis [7-9]. Ne-
vertheless, to the best of our knowledge, the present study
reports the largest cohort treated with XELOX/bevacizu-
mab combination so far.
The age structure of patients in our study was similar
to that reported in the NO16966, BRiTE, and BEAT
studies. The present analysis used similar approach and
was of comparable size as the Medicare analysis that,
however, only included patients aged 65 year or older
and only those with synchronous metastases [9]. This
patient profile in the Medicare cohort may explain the
difference in OS of almost 12 months compared to our
study. The proportion of patients previously receiving
adjuvant treatment was lower in the present study com-
pared to the BEAT and BRiTE cohorts. Although the
median PFS of patients in our cohort was similar to that
reported in the above studies, the median OS was sub-
stantially longer, reaching 30 months for patients in the
XELOX/bevacizumab subgroup. The favourable survival
may be due to a more recent patient cohort in the
present study and, possibly, patient selection. Gradual
incremental improvements in OS have been observed in
mCRC over the past decade because of the introduction
Table 2 Results of the multivariable cox model for progression-free survival
Variable Risk category Beta HR 95% CI p-value
Sex Male/female −0.06 0.95 (0.85-1.05) 0.310
Age >65 years/<65 years −0.03 0.97 (0.87-1.08) 0.580
Site of primary tumour Rectum/colon 0.08 1.08 (0.97-1.20) 0.170
Primarily metastatic M1/M0 0.11 1.12 (1.00-1.25) 0.057
Number of metastatic sites 2/1 0.33 1.39 (1.24-1.56) <0.001
3 and more/1 0.51 1.66 (1.41-1.95) <0.001
CT regimen XELOX/FOLFOX −0.05 0.95 (0.84-1.08) 0.400
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tantly, the administration of the most expensive cancer
drugs including bevacizumab has been centralised in the
Czech Republic. It is possible that the centralisation of
patients into cancer centres is partly responsible for the
excellent survival results. In contrast, the median num-
ber of patients enrolled during a 16-month period per
centre was only eight for the 248 sites participating in
the BRiTE observational study [8].
For obvious reasons, the present analysis does not an-
swer the question of the benefit of adding bevacizumab
to an oxaliplatin-based regimen. The addition of bevaci-
zumab has been shown to prolong OS in patients with
irinotecan-based regimens, but the data on patients
treated with the combination chemotherapy containing
oxaliplatin are more ambiguous. In the NO 16966 trial
that randomized patients using a 2 × 2 factorial design
between XELOX and FOLFOX4 with or without beva-
cizumab, the addition of bevacizumab significantly pro-
longed PFS. However, statistically significant superiority
could be demonstrated only in the subgroup of patients
treated with XELOX but not FOLFOX. Adding bevaci-
zumab to oxaliplatin-based chemotherapy resulted in a
trend to prolongation of OS that did not reach statistical
significance [2,11]. The lack of survival improvement
after adding bevacizumab to oxaliplatin-based chemo-
therapy that contrasted with a significant effect in pa-
tients treated with irinotecan-based regimens has also
been reported in the retrospective Medicare analysis [9].Table 3 Results of the multivariable Cox model for overall su
Variable Risk category
Sex Male/female
Age >65 years/<65 years
Site of primary tumour Rectum/colon
Primarily metastatic M1/M0
Number of metastatic sites 2/1
3 and more/1
Chemotherapy regimen XELOX/FOLFOXThe prognostic factors identified in the present cohort
are well established for the mCRC population. The risk
of death was almost two times higher in patients with
three or more metastatic sites at the start of bevacizu-
mab therapy compared to patients with only one meta-
static site. The presence of two metastatic sites was
associated with almost 50% increase in the risk of death.
The risk of death was 34% higher in patients with meta-
static CRC at diagnosis compared to patients with recur-
rent disease.
Of note, while the overall response rates in the FOLFOX/
bevacizumab and XELOX/bevacizumab cohorts were
similar, in the FOLFOX/bevacizumab group, there were
significantly less patients who had disease stabilisation
(31.4% versus 40.5%, respectively) and conversely more
patients who had progressive disease than in the XELOX/
bevacizumab group (15.0% versus 6.5%, respectively).
The possible differential association between OS and
KRAS status for the two backbone regimens that reached
borderline statistical significance in our analysis is surpris-
ing. We found that there was a trend to improved survival
in patients with KRAS wild-type tumours versus those
with KRAS mutated tumours in the XELOX/bevacizumab
subgroup but in the FOLFOX/bevacizumab subgroup.
This finding may merit further research.
Patients who had received prior adjuvant chemo-
therapy treated within the NO 16966 trial had better
PFS with FOLFOX alone than with FOLFOX/bevacizu-
mab [5]. We have carried out a similar analysis on ourrvival
Beta HR 95% CI p-value
0.00 1.00 (0.86-1.15) 0.950
−0.03 0.97 (0.83-1.13) 0.680
0.11 1.12 (0.97-1.29) 0.130
0.29 1.34 (1.14-1.56) <0.001
0.38 1.47 (1.26-1.71) <0.001
0.66 1.94 (1.57-2.39) <0.001
−0.10 0.91 (0.76-1.09) 0.290
Table 4 Overall survival and progression-free survival in different subgroups of mCRC patients
Patient subgroup First-lineregimen n
Overall survival Progression-free survival
Median survival (months) 95% CI p Median survival (months) 95% CI p
Stage I-III at diagnosis




XELOX 365 33.2 28.7-41.9 12.1 11.1-13.7
Stage IV at diagnosis




XELOX 608 28.5 25.1-32.9 11.2 10.1-12.2
Without adjuvant chemotherapy




XELOX 704 28.7 25.5-31.8 11.2 10.5-12.1
With adjuvant chemotherapy




XELOX 262 35.8 28.2-43.8 12.1 11.1-14.0
Wild type KRAS




XELOX 199 38.8 34.2-45.8 10.8 9.8-12.4
Mutant KRAS




XELOX 123 28.4 22.9-42.2 10.0 9.3-11.9
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differences between the two studied combinations for
any clinically defined patient subgroup (Table 4).
The present analysis has obviously several weaknesses
that are partly due to its retrospective nature. Selection
bias cannot be excluded as fitter patients could have
been preferentially allocated to XELOX chemotherapy.
Data on initial performance status are missing in one-
half of the patients and there is some imbalance in the
proportion of primarily metastatic patients between the
cohorts. The registry does not provide data on the
removal of primary tumours in patients with primarily
metastatic colorectal cancer and on variant FOLFOX
regimens that may be used in some centres, although
these variables would be unlikely to skew the results of
survival analysis.
No centralised review of radiological response was per-
formed and the data on PFS may be less reliable given the
number of centres involved and different patterns of care,
including radiological imaging, in each centre. We were
not able to extract valid data on metastasectomies from
the registry for the entire period of study. On the other





Gastrointestinal perforation 3 (0.1%)
Arterial thromboembolic event 8 (0.4%)
Venous thromboembolic event 17 (0.8%)
Proteinuria 5 (0.2%)against the national registry of deaths. In general, OS data
are more reliable for this type of registry-based retrospec-
tive studies, and some studies, including the study recently
published by Meyerhardt et al., analysed only OS [9].
The incidence of adverse events was lower in the
present analysis than that reported in prospective trials.
The registry was focused on bevacizumab and the atten-
ding physicians apparently tended to report only events
associated with bevacizumab and not toxicities linked to
the chemotherapy backbone. Also, asymptomatic throm-
botic events detected only on imaging, such as visceral
thrombosis were unlikely to be reported. Because the inci-
dence of severe or even life-threatening toxicities such
as thromboembolism or gastrointestinal perforation that
usually lead to treatment interruption or modification is
less likely to be affected by underreporting, only grade 3–
5 adverse events are reported here. Another reason for the
relatively low incidence of adverse events could be the se-
lection bias that is inherent to registry-based studies.
On the other hand, the strong point of the present ana-
lysis is that it shows similar activity of the combination
of bevacizumab and FOLFOX/XELOX chemotherapies in
real-world medicine.mab-related adverse events
n = 973 n = 1218
XELOX FOLFOX p-value
15 (1.5%) 13 (1.1%) 0.344
1 (0.1%) 9 (0.7%) 0.050
0 (0.0%) 3 (0.2%) 0.259
4 (0.4%) 4 (0.3%) 0.739
11 (1.1%) 6 (0.5%) 0.139
2 (0.2%) 3 (0.2%) 1.000
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Data from a large, registry-based retrospective analysis sug-
gest that XELOX and FOLFOX regimens in combination
with bevacizumab are equipotent in the first-line treatment
of mCRC. In a multivariable model, the number of meta-
static sites was identified as the most significant predictor
of PFS and, together with the presence/absence of meta-
static disease at diagnosis, also for OS.
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